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Tuberculosis continues to be a global health threat,
making bicyclic nitroimidazoles an important new
class of therapeutics. A deazaflavin-dependent nitro-
reductase (Ddn) from Mycobacterium tuberculosis
catalyzes the reduction of nitroimidazoles such as
PA-824, resulting in intracellular release of lethal
reactive nitrogen species. TheN-terminal 30 residues
of Ddn are functionally important but are flexible or
accessmultiple conformations, preventing structural
characterization of the full-length, enzymatically
active enzyme. Several structures were determined
of a truncated, inactive Ddn protein core with and
without bound F420 deazaflavin coenzyme as well as
of a catalytically competent homolog from Nocardia
farcinica. Mutagenesis studies based on these struc-
tures identified residues important for binding of F420
and PA-824. The proposed orientation of the tail of
PA-824 toward the N terminus of Ddn is consistent
with current structure-activity relationship data.
INTRODUCTION
It is estimated that one-third of the world’s population is infected
with Mycobacterium tuberculosis (MTB) (Dye et al., 1999). In
2008, 11.1 million reported cases of active tuberculosis (TB) re-
sulted in 1.3 million deaths worldwide (World Health Organiza-
tion, 2011). MTB is able to evade the human immune response
in part by triggering formation of insulating hypoxic granulomas
following infection of pulmonary macrophages. Bacilli within
this environment have adapted to slowly replicate and respire,
making them tolerant of many drugs. This resistant state is
thought to contribute to the prolonged combination chemo-
therapy required to cure patients (Barry et al., 2009; Boshoff
and Barry, 2005). Lack of compliance with treatments lasting
up to 9 months contributes to the emergence of resistant strains
(Sharma and Mohan, 2006). The spread of multidrug-resistant
strains and the rise of TB as a secondary infection in AIDSStructure 20, 101patients (Corbett et al., 2003) have increased the urgency of
identifying new drugs to provide more practical treatments.
Recently, bicyclic 4-nitroimidazoles have emerged as a new
class of drug candidates against TB (Stover et al., 2000). PA-824
and OPC-67683 (Figure 1) are currently in phase II clinical trials
and have shown efficacy against aerobically replicating bacilli,
nonreplicating bacilli within hypoxic granulomas, and multidrug-
resistantstrains inpreclinical animalmodels (Huetal., 2008;Hurdle
et al., 2008;Matsumoto et al., 2006; Stover et al., 2000; Tyagi et al.,
2005). Both compounds not only disrupt mycolic acid synthesis,
important for cell wall formation under aerobic conditions (Matsu-
moto et al., 2006; Stover et al., 2000), but also show considerably
more complex cellular effects, particularly under anaerobic con-
ditions where there are clear signs that respiratory poisoning is
responsible for bactericidal activity (Manjunatha et al., 2009).
PA-824 and OPC-67683 are prodrugs that appear to undergo
similar reduction reactions (Anderson et al., 2008; Maroz et al.,
2010; Matsumoto et al., 2006; Singh et al., 2008; Thompson
et al., 2009).Characterizationof in vitro selectedPA-824-resistant
mutants identified lesions ingenescoding for enzymes involved in
F420 coenzyme (Figure 1) biosynthesis, F420-dependent glucose-
6-phosphate dehydrogenase (FGD1), and Rv3547, a protein of
unknown cellular function. Strains with disruptions in fgd1 and
Rv3547 could be made sensitive to PA-824 by complementation
with intact copies of the respective genes (Manjunatha et al.,
2006a; Stover et al., 2000). Both FGD1 and Rv3547 are F420-
dependent enzymes, but only Rv3547 is capable of reducing
PA-824 directly (Manjunatha et al., 2006a), whereas FGD1 recy-
cles the coenzyme to the reduced form. Because of its enzymatic
activity,Rv3547wasnamedadeazaflavin-dependent nitroreduc-
tase (Ddn). The F420-dependent reduction of PA-824 has been
shown to produce a mixture of three stable metabolites as well
as a release of reactive nitrogen species (Singh et al., 2008). Of
the three metabolites, the levels of a des-nitro species correlate
best with nitric oxide (NO) release and anaerobic bactericidal
activity. The role of NO as primary toxin is supported by previous
suggestions that NO production by macrophages controls TB in
murine models and in human macrophage cultures (MacMicking
et al., 1995; Rich et al., 1997).
MTB proteomics studies have suggested that Ddn may be
a peripheral membrane protein (Sinha et al., 2002, 2005), but–112, January 11, 2012 ª2012 Elsevier Ltd All rights reserved 101
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Figure 1. Structures of Bicyclic 4-Nitroimidazoles and of the F420
Coenzyme
Purified F420 used in this work is a mixture with primarily four, five, or six
glutamate residues. For simplicity, only the two residues that could be refined
during costructure determination are shown.
Figure 2. Activity of Ddn Constructs and Homologs
The activities of several Ddn constructs were tested to identify those that could
reduce PA-824, measured by an increase of fluorescence intensity (FI) of
oxidized F420. None of the soluble, nonaggregated monomeric truncations or
mutants showed activity (data plotted for F16A-F17D-W20D-I24A-W27D-
M28A [white diamonds]; D15E-F16A-F17D-W20D-I24A-W27D [white circles];
F16A-F17D-W20D-I24A-W27E [white squares]; ND30 [black circles]; ND33
[black up triangles]; D14-22 [black down triangles]; D14-30 [black diamonds]).
Homologous proteins for which structures were determined were also tested.
Only nfa33440 showed activity toward PA-824. Assay conditions: 30–50 nM
enzyme, 30 mM PA-824, 20 mM F420H2, 0.2 M Tris-HCl (pH 8.0), 0.01% Triton
X-100, 25C. Similar results were obtained with 300 nM enzyme (data not
shown). See Figures S1–S3.
Structure
Structure of PA-824-Activating MTB Nitroreductaseits biological substrate and function remain unknown, and there
is low sequence homology to any protein of known cellular func-
tion (Singh et al., 2008). Homologs do exist in several species,
mostly within Actinobacteria, although not inM. leprae, the etio-
logic agent of human leprosy, which is resistant to PA-824
(Manjunatha et al., 2006b). The F420 coenzyme is only present
in select groups of archaea and bacteria and is an obligate
two-electron (hydride) donor with a more negative redox poten-
tial than nicotinamide coenzymes (Bair et al., 2001; Graham
et al., 2003; Jacobson and Walsh, 1984).
In order to better understand the mechanism of activation of
PA-824, we determined the structure of a truncated version of
Ddn in the presence and absence of the F420 coenzyme.
Comparison of these structures and NMR observations reveals
regions of the protein that are conformationally flexible and
undergo changes upon cofactor binding. We have also solved
the structures of two full-length homologs from Nocardia
farcinica, one of which is catalytically competent for PA-824
reduction in vitro. Structural and mutational studies with Ddn
and the active homolog identified key residues in the active
site of this enzyme family. The data presented in this study
provide structural insights into the Ddn-catalyzed activation of
bicyclic 4-nitroimidazole prodrugs, a process key to the function
of this important class of antitubercular clinical candidates.
RESULTS
Design and Construction of Soluble Forms of Ddn
and Homologous Proteins
Currently, a maltose-binding protein (MBP) fusion (Kim et al.,
2009b; Singh et al., 2008) is the only full-length wild-type102 Structure 20, 101–112, January 11, 2012 ª2012 Elsevier Ltd All rDdn construct that can be expressed as soluble protein in
Escherichia coli. This MBP fusion protein activates PA-824
in vitro but is highly aggregated, as determined by size-exclusion
chromatography. Untagged Ddn produced by proteolytic
removal of MBP is also highly aggregated. Proteins that exist
as soluble aggregates rarely produce crystals (Klock et al.,
2008) and exhibit line-broadened NMR spectra, making them
difficult targets for structural biology. Indeed, despite significant
efforts, we have not obtained any suitable crystals or NMR
spectra for full-length Ddn.
To identify proteins more suitable for structural biology, we
tested a series of 17 truncation mutants (see Table S1 available
online). Deletion of 26–50 residues from the N terminus showed
high levels of soluble protein expression, and removal of 30, 33,
or 40 residues produced nonaggregated monomeric protein
(Figure S1A). Well-dispersed signals for 113 of 114 nonproline
residues were observed by 1H-15N-HSQC NMR spectroscopy
for uniformly 15N-labeled ND30 Ddn protein, suggesting a well-
defined three-dimensional structure (Figure S1B). This sample
also showed significant chemical shift perturbation upon addi-
tion of oxidized or reduced coenzyme F420, demonstrating tight
binding of the coenzyme and suggesting that this construct
adopts a physiologically relevant form (Figure S1B). None of
the N-terminally truncated soluble constructs were catalytically
competent as assessed by monitoring oxidation of F420 in the
presence of PA-824 (Figure 2), suggesting that the N terminus
is important for substrate binding or catalysis.
The N terminus of Ddn is predicted to contain an amphipathic
a helix at residues 13–28 with a highly hydrophobic side (Fig-
ure S2) that may be causing aggregation of full-length Ddn.
Consequently, we made a series of 36 mutants designed to
disrupt this hydrophobic surface, including combinations of up
to six point mutations (Table S1). Some combinations of threeights reserved
Table 1. Data Collection and Refinement Statistics
Crystal
Apo-0
(ND33 Ddn)a
Apo-1
(ND30 Ddn)
Apo-2
(ND33 Ddn)
Holo-1
(ND40 Ddn +
F420-ox)
Holo-2
(ND40 Ddn +
F420-ox)
nfa33440
(+F420-ox)
nfa18080
(+F420-ox)
PDB ID code 3R5L 3R5P 3R5R 3R5W 3R5Y 3R5Z
Data Collection
Space group C2221 C2221 P3221 C2 P21 P43 P21
Cell dimensions
a, b, c (A˚) 67.37, 71.01,
50.74
67.17, 71.04,
50.53
96.18, 96.18,
33.70
146.95, 91.71,
86.50
85.34, 89.42,
127.68
71.96, 71.96,
115.47
39.70, 56.94,
66.00
a, b, g () 90, 90, 90 90, 90, 90 90, 90, 120 90, 119.53, 90 90, 96.29, 90 90, 90, 90 90, 105.52, 90
Resolution (A˚)b 50–1.75
(1.81–1.75)
50–1.55
(1.61–1.55)
50–1.85
(1.92–1.85)
50–2.10
(2.18–2.10)
50–1.80
(1.86–1.80)
50–1.80
(1.86–1.80)
50–1.50
(1.55–1.50)
Rmerge
b 8.8 (42.5) 9.8 (62.6) 11.3 (57.2) 11.2 (47.3) 7.3 (72.2) 8.8 (66.5) 8.0 (47.3)
I/sb 54.6 (5.7) 27.5 (2.5) 12.4 (1.2) 10.7 (1.9) 22.9 (1.6) 28.2 (1.9) 18.0 (1.6)
Complete (%)b 99.1 (91.0) 97.7 (99.5) 97.9 (81.6) 97.9 (98.1) 97.5 (96.3) 100 (100) 93.5 (82.1)
Redundancyb 20.6 (18.8) 3.9 (3.3) 5.1 (3.6) 2.4 (2.5) 3.1 (3.2) 5.4 (5.4) 2.3 (1.8)
Phasing
Number found 2
Figure of merit 0.35
Refinement
Resolution (A˚) 35.52–1.55 41.64–1.85 46.67–2.10 42.17–1.80 45.03–1.80 37.52–1.50
Number of reflections 16,624 14,350 53,828 159,341 51,143 38,957
Rwork/Rfree 18.0/21.1 17.1/20.3 22.7/26.3 17.3/20.6 17.3/21.4 16.6/19.2
Number of atoms
Protein 942 927 4,465 8,790 4,435 2,261
F420 (and other) 12 (MES) 10 (SO4
2) 265 530 212 111 (SO4
2)
Water 120 108 438 1,280 486 241
B factors (A˚2)c 24.61 24.63 22.94 31.01 29.37 21.34
Rmsds
Bond lengths (A˚) 1.734 1.747 1.039 1.568 1.131 1.490
Bond angles () 0.015 0.018 0.006 0.013 0.008 0.013
a For descriptions of the protein constructs, see also Table S1.
b Values in parentheses are for the highest-resolution shell.
c Average over all atoms.
Structure
Structure of PA-824-Activating MTB Nitroreductaseor more mutations resulted in soluble monomeric protein but did
not show additional peaks in 1H-15N-HSQC spectra compared to
the truncation mutants (Figure S3A), indicating that the N
terminus in these mutants undergoes conformational exchange
processes in the milli- to microsecond timescale. Other muta-
tions designed to stabilize the hypothetical helix through salt
bridges also resulted in monomeric proteins, but chemical shift
analysis of HSQC spectra (Figure S3B) suggested that the
mutated N termini did not interact with the core of the protein.
All monomeric full-length mutant constructs have so far failed
to produce diffracting protein crystals despite extensive
screening of conditions in the presence and absence of coen-
zyme and PA-824. In addition, none of the mutant monomeric
full-length proteins showed activity toward PA-824 even at
high enzyme concentration (300 nM).
In parallel, we expressed several Ddn homologs that were
chosen to have a range of lower predicted isoelectric points,
a trait that has been shown to enhance crystallization in the
context of structural genomics (Slabinski et al., 2007). TheseStructure 20, 101proteins were tested for activity and put into crystallization trials
to determine protein structures that could add to our under-
standing of the full-length Ddn enzyme for which only the core
structure could be determined.
Ddn Structure Determination
An initial Ddn crystal structure was solved by single-wavelength
anomalous dispersion (SAD) phasing of a 1.75 A˚ data set from
a crystal belonging to space group C2221 of the ND33 construct
with selenomethionine incorporated (Apo-0 in Table 1). As ex-
pected (Manjunatha et al., 2006a; Taylor et al., 2010), the back-
bone trace shows high similarity to proteins in the split barrel-like
family of flavin-binding proteins (Figure 3A). The initial structure
was then used to solve the structure of the longer ND30
construct by molecular replacement based on a 1.55 A˚ data
set (Apo-1 in Table 1; Figure 3B) and of a 1.85 A˚ resolution
ND33 crystal (P3221 space group; Apo-2 in Table 1). All but the
first five amino-terminal residues could be built into the electron
density for both crystal forms (36–151 and 39–151, respectively).–112, January 11, 2012 ª2012 Elsevier Ltd All rights reserved 103
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Figure 3. Ddn Structures with and without Coenzyme F420
(A) Topology of split barrel-like fold oriented to the models. Arrows point to the
post-b3 loop discussed in the text for orientation throughout the figure.
(B) Cartoon of Apo-1 structure showing split barrel-like fold.
(C) Cartoon of one monomer from Apo-1 (orange) aligned with one monomer
from Apo-2 (purple) and showing Y130, Y133, Y136, and S78 for comparison.
Y130 and Y136 are labeled.
(D) Cartoon of one monomer from the Holo-1 structure with F420 (magenta).
The post-b3 loop (arrow) is repositioned to create the pocket for binding of the
deazaflavin ring system. Key waters are shown as red spheres.
(E) Surface rendering of the pentameric structure from Holo-1 shows
a complementary groove with positive (blue) charges near the negatively
charged tail of F420. A small pocket is formed near the flavin ring system but is
not enclosed by the protein monomers or pentamers. Although the biological
relevance is unclear, the pentamer provides room for the missing N termini
(center of ring or packed on the front face). The front face also packs against
a second pentamer in both crystal forms, occluding the active sites or
potentially allowing crosstalk between active sites.
(F) Cartoon of onemonomer fromApo-1 (orange) aligned to onemonomer from
Holo-1 (cyan; F420 in magenta) and showing Y130, Y133, Y136, and S78 for
comparison. See Table S2 for NMR characterization of ND30 Ddn with and
without coenzyme.
Structure
Structure of PA-824-Activating MTB NitroreductaseThe asymmetric units (ASUs) for the Apo-1 and Apo-2 crystals
both contain single molecules with similar structures (root-
mean-square deviation [rmsd] is 0.96 A˚). This alignment omits
14 of 113 shared Ca atoms because of conformational differ-104 Structure 20, 101–112, January 11, 2012 ª2012 Elsevier Ltd All rences (Figure 3C) in the same regions that differ upon coenzyme
binding as discussed below.
Cocrystals of the ND40 construct with oxidized F420 were also
obtained in two space groups and were solved by molecular
replacement (Holo-1 in C2 at 2.1 A˚ resolution and Holo-2 in
P21 at 1.8 A˚ resolution, with an rmsd for one chain of 0.3 A˚
over 109 aligned Ca atoms; see Table 1). The data from both
crystals yielded clear difference electron density for the F420
coenzyme, with two glutamate residues in the tail that could be
easily positioned (Figure 3D). Although the F420 preparation
included larger polyglutamate tail species, only two glutamates
could be visualized (F420-2), consistent with the structure of
FGD1 crystallized with a similar preparation (Bashiri et al.,
2008) and the recent observation that F420-2 and F420-5 bind
with similar affinity to Ddn (Gurumurthy et al., 2012). The crystal
packing combined with crystallographic symmetry operations
reveals the same decameric ring structure in both structures
(Figure 3E), with five monomers in the ASU of Holo-1 and ten
in Holo-2 (two rings per ASU). Although the decamer structure
includes extensive intersubunit packing, its relevance to the
native quaternary structure and function remains unknown
because of the difficulties of studying the full-length enzyme.
Analysis ofDdnStructures andConformational Changes
upon Binding to F420
The split barrel-like fold is characterized by a central six-
stranded antiparallel b barrel in a Greek key topology with four
a helices: A at the N terminus (the putative helix removed for
Ddn structure determination), B after an extended loop between
strands b3 and b4, and C and D between strands b5 and b6 (Fig-
ure 3A). In Ddn, strands b2, b1, b4, and b5 form the larger sheet at
the base of the molecule, whereas strands b2 and b5 are elon-
gated to also interact with the shorter strands b3 and b6 in the
middle of the molecule (Figure 3B).
In structures Holo-1 and Holo-2, F420 binds to a groove on the
surface of Ddn (Figures 3D and 3E) through a series of hydrogen
bonds and several salt bridges between positive charges on
Ddn and the negatively charged phosphate and tail of the coen-
zyme (Figure 4). The last visible glutamate of the F420 tail lies near
the b1-b2 hairpin within hydrogen-bonding range of the side
chains of R54, T56, and R60 as well as the main chain of K55
and T56. The more proximal glutamate H bonds with the side
chain of N91 from helix B. The phosphate of F420 sits near the
complementary positive charge of K79 and H bonds to the
amides of M87 and W88 from the loop after strand b3. The ribityl
moiety is stabilized by H bonds to the side chain of W88 (loop)
and the main-chain carbonyl of P63 (strand b2). The deazaflavin
ring system is stabilized by H bonds with the main chain of A76
and K79 and the side chain of Y133 (helix D). Additionally, there
are waters in both costructures that mediate interactions
between protein and coenzyme. The sum of these interactions
results in the Re face of F420 being presented for reaction with
PA-824.
The largest conformational changes between the apo- and
F420-bound structures occur near the deazaflavin ring (Figure 3F).
The loop following strand b3 (residues 76–85) shifts away from
the binding site in the presence of coenzyme in order to form
the direct contacts to the phosphate and deazaflavin hetero-
cycle outlined above, with the Ca of S78 moving approximatelyights reserved
Figure 4. Analysis of the Interactions between Ddn and F420
Onemonomer from theHolo-1 structure (chains E and J) was input to LIGPLOT
(Wallace et al., 1995) to exemplify the extensive hydrogen-bond and hydro-
phobic interactions between protein and cofactor. Bonds for the protein are
colored brown; F420 bonds are purple (black, carbon; blue, nitrogen; red,
oxygen; yellow, sulfur; purple, phosphorus). H bonds (3.2 A˚ cutoff) are indi-
cated with green dashed lines; hydrophobic contacts are indicated with red
dashes.
Structure
Structure of PA-824-Activating MTB Nitroreductase4 A˚ in Holo-1 versus Apo-1 (Figures 3D and 3E). In Holo-1 and
Holo-2, this loop packs against a helix D (residues 131–139)
and generally exhibits lower mobility, indicated by a drop in
atomic displacement parameters (ADPs) relative to the apo
structures. In Apo-1 and Apo-2, a helix D is highly disrupted,
with repositioning of residues 129–144 relative to the holo-
enzyme structures complementing movement of the post-b3
loop (Figure 3C). In Apo-1, the side chain of Y136 is flipped
away from the F420 binding site, with the oxygen atom moving
19 A˚ relative to the Holo-1 structure. In Apo-2, this helix stops
at Y136 and instead a helix forms upstream from residues
139–143, and residues 136–143 display higher ADPs. NMR
data also suggest that the post-b3 loop and helix D are dynamic.
Although 98% of the 1H-15N peaks for ND30 apo-Ddn have
been assigned as part of this study, the spectra of the protein
with F420 have proven less tractable, with the longest unassigned
segments at residues 75–88 (post-b3 loop) and 122–148
(a helices C and D, and b6) and a shorter segment at 62–66
(b2) (Table S2). Approximately 75% of the peaks associated
with these regions were missing or were too broad to be used
for assignment. These data all suggest that portions of the
protein are conformationally flexible, which may be functionally
relevant, as exchange of the coenzyme would be required to
complete each catalytic cycle.Structure 20, 101Structures of Ddn Homologs
In order to characterize a full-length enzyme including the N
terminus, we also determined the structure of nfa33440,
a homolog from N. farcinica sharing 42% sequence identity to
Ddn and that was active in the PA-824 in vitro assay (Figure 2).
The structure of this protein was solved by molecular replace-
ment using the Ddn structure. Although an initial apo structure
lacked density for the first 37 amino acids, a cocrystal of
nfa33440 with F420 confirmed that the overall structure and
coenzyme binding are very similar to that of Ddn (Figure 5A;
rmsd is 0.95 A˚ over 109 aligned Ca atoms to Holo-1). The N
terminus of nfa33440 is represented in the electron density start-
ing at residue 6, showing an extended sequence packed against
the core of the protein followed by a short a helix flanking the F420
binding site. 1H-15N-HSQC NMR spectra were collected for
nfa33440 alone, in the presence of F420, and with F420 and PA-
824 (Figure S4). The spectrum of apo-nfa33440 includes approx-
imately 107 1H-15N peaks out of an expected 135. Although
interpretation is uncertain without assigning the spectrum, these
data, along with the lack of density for the N terminus in the apo-
nfa33440 crystal, suggest that nfa33440 in solution consists of
a structured core with the N terminus undergoing conformational
exchange processes similar to the Ddn mutants. Addition of F420
to nfa33440 resulted in a spectrumwith approximately 90 peaks.
This is again similar to ND30 Ddn, in which parts of the active site
appear to undergo conformational exchange in the presence of
coenzyme. Addition of excess PA-824 to nfa33440 resulted in
chemical shift perturbation of a few of the weaker peaks (Fig-
ure S4), supporting the hypothesis that it is residues in the active
site that are undergoing dynamic processes.
The full-length structure of a second, inactive homolog,
nfa18080 from N. farcinica, was solved by X-ray crystallography
in the presence of F420 (rmsd to Holo-1 is 1.1 A˚ over 109 aligned
Ca atoms). The protein core, short N-terminal helix, and coen-
zyme binding site are conserved for nfa18080 relative to
nfa33440. Electron density for the N terminus of nfa18080 starts
at residue 5 and approaches the active site of a neighboring
monomer in the crystal. The side chain of Y7 of one monomer
stacks on top of the exposed Re face of F420 (Figure 5B) of
another monomer at the location where one would expect the
enzyme substrate to bind (Fraaije and Mattevi, 2000). The
homolog structures provide insight into possible orientation of
some conserved N-terminal residues in relation to the active
site. However, because of low sequence homology (Figure 5C;
about 20% identity to Ddn residues 1–30) and flexibility of the
N-terminal helix, these structures do not provide a reliable model
for the missing Ddn N terminus. Parts of the active sites of Ddn
therefore cannot be defined structurally, limiting the utility of
these structures for elucidating themechanism of NO generation
from the PA-824 prodrug.
Mutagenesis Studies and the Putative Binding Mode
of PA-824 to Ddn
Attempts to determine the structure of a ternary complex of Ddn
or a homolog with F420 and PA-824 or several analogs, by coc-
rystallization or soaking, were unsuccessful. Modeling was
used to visualize the binding mode of PA-824 (Figure 6A), using
the Holo-1 structure with F420 and placing the imidazole group of
PA-824 at an appropriate distance from C5 of the flavin ring for–112, January 11, 2012 ª2012 Elsevier Ltd All rights reserved 105
A B
C
Figure 5. Structures of Proteins Homolo-
gous to Ddn
(A) Superposition of Holo-1 (blue), nfa33440 (red),
and nfa18080 (green) (see rmsd values in the text).
The structures are shown aligned on coenzyme
F420, which is represented by strong electron
density in the same pose in all three data sets with
variation mainly in the glutamate tail.
(B) Detail of nfa18080 residue Y7 from one
symmetry mate positioned in the active site of the
neighboring monomer in the crystal. The tyrosine
side chain interacts with the main chain of S70
(S78 in Ddn) and is positioned within 4 A˚ of the Re
face of the flavin ring (measurement shown to C5).
ResiduesW122, Y125, and Y128 (Ddn Y130, Y133,
Y136) are also shown for reference.
(C) Sequence alignment denoting identity (red) to
Ddn from MTB. Secondary structure is conserved
among the three holo-enzyme structures and is
identified with reference to the topology map in
Figure 3A (numbered b strands; lettered a helices)
with the exception of a helix A, which is underlined
(predicted for Ddn; experimental for homologs).
See also Figure S4 for NMR characterization of
nfa33440.
Structure
Structure of PA-824-Activating MTB Nitroreductasehydride transfer (based on observations for other flavin-binding
proteins; Fraaije and Mattevi, 2000). In the lowest-energy model,
the nitroimidazole group of PA-824 is located near the Re face
of F420, with the nitro group H bonded with the side chains of
S78, Y130, and Y136 (Figure 6). Notably, S78 in Ddn and S72
in nfa33440 are bound to a water modeled near some chains
of the crystal structures (shown for Holo-1, chain E in Figure 3D),
which may mimic binding to one oxygen atom of the nitro
group of PA-824. To test this hypothesis, we generated single
point mutants in the full-length MBP-Ddn fusion protein as
well as in nfa33440 and determined their enzymatic activity
toward PA-824 at saturating concentrations of F420 (Table 2).
Mutation of S78 (nfa33440 S72) resulted in loss of activity, as
did perturbation of nearby residues likely to help position S78
(Ddn R142, I144; nfa33440 R136, I138). The proposed role of
the Ddn Y130 (nfa33440 Y124) hydroxyl for substrate binding
and orientation was also substantiated because mutation of
Tyr to Phe significantly lowered catalytic competence in either
enzyme. The activity of Ddn Y136 (nfa33440 Y130) was not
significantly compromised by mutation to Phe, but was by muta-
tion to Leu or Val. These data suggest that Y136 may not be
directly involved in hydrogen bonding or proton relay but
instead may contribute to aligning other aromatic residues in
the active site.
Mutation of Y133 (nfa33440 Y127) resulted in reduced enzy-
matic activity (Table 2), suggesting a critical role for this residue
in anchoring the deazaflavin ring of the coenzyme in the active
site (Figure 4). Likewise, Y65, A76, and K79 are all likely to play106 Structure 20, 101–112, January 11, 2012 ª2012 Elsevier Ltd All rights reserveda role in stabilizing the F420 complex.
They uniformly resulted in loss of enzy-
matic activity. Among the equivalent
nfa33440mutants, decreased F420 affinity
(Table S3) was observed for M59A (Ddn
Y65), as assessed qualitatively by NMR.In the case of the nfa33440 mutants, we were able to confirm
by NMR that mutations of these key residues did not result
in large structural changes (Figure S5) or loss of affinity for
F420 binding (M59A being the exception; measurable lower
exchange rate) (Table S3). However, S72V, R136A, and I138A
exhibited altered affinity for PA-824 (Table S4; Figure S6).
Mutagenesis and Characterization of the N Terminus
of Ddn
The loss of PA-824 activity in all truncated constructs suggested
the importance of the N terminus, and studies of the intrinsic
tryptophan fluorescence suggest that it is primarily important
for PA-824 binding. Ddn contains five Trp residues (positions
20, 27, 88, 123, and 139), and Ddn protein exhibits an intrinsic
fluorescence emission spectrum with a maximum at 330 nm
when excited at 280 nm (Figure 7A). In contrast, the ND30 Ddn
construct showed negligible intrinsic fluorescence, suggesting
that residues W20 and W27 are largely responsible for the
observed signal. At saturating levels of F420, about 60% of tryp-
tophan fluorescence was quenched, whereas PA-824 was able
to quench nearly all intrinsic fluorescence (Figure 7A). Similar
results were obtained with the MBP-Ddn fusion proteins,
providing a direct assay for binding of PA-824 and F420 to Ddn,
resulting in an apparent Kd of 31 mM for PA-824 and 1.0 mM for
F420 (Figures 7B and 7C).
The proposed binding mode of PA-824 orients the hydro-
phobic tail toward the expected location of the N terminus of
Ddn. Analogues of PA-824 clearly show a preference for
AB
Figure 6. Putative Binding Mode of PA-824
(A) The 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine core of PA-824
(yellow) was modeled into the Holo-1 structure near the F420 coenzyme.
(B) Schematic showing residues thought to be important for PA-824 binding
and catalysis. F16, F17, and W20 were not present in the X-ray structures of
Ddn. Based on the mutation data, these residues are included to depict their
potential interactions with the hydrophobic tail group of PA-824.
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and suggest the possibility that hydrophobic aromatic residues
within the N terminus play a critical role in substrate binding.
We therefore created mutations at F16, F17, and W20 to test
this hypothesis (Table 2). Single mutations F16L, F16V, or
F16A reduced activity of the enzyme toward PA-824 by 60%
whereas mutations of F17 or W20 resulted in more variable
effects, with loss of 15%–50% of activity as measured in terms
of kcat/KM. Because the apparent flexibility of this region of the
protein might allow PA-824 to interact with more than one of
these residues, we next studied double and triple mutations.Structure 20, 101The F16A/F17A mutant still possessed 40% of the activity of
the wild-type enzyme, but the triple mutant, F16A/F17A/W20A,
had only about 8% activity. Analysis of PA-824 and F420 binding
by fluorescence spectroscopy showed that both the W20 single
mutants and the triple mutant have decreased affinity to PA-824,
whereas additional loss of activity in the triple mutant is likely due
to a decreased affinity for F420. Circular dichroism measure-
ments were used to confirm that none of thesemutations caused
drastic changes to the overall secondary structure of the protein
(Figure S8; Table S5).
DISCUSSION
Four unique structures of Ddn and the structures of two homol-
ogous proteins were determined. The structure of the Ddn
protein core with coenzyme F420 bound confirms that this protein
adopts a split barrel-like fold common among flavin-binding
proteins, whereas the N terminus appears to mediate aggrega-
tion that prevented study of the full-length WT protein. Details
of coenzyme binding and subsequent mutagenesis experiments
identified key residues for substrate binding and positioning in
the active site. We have postulated a binding mode for PA-824
that involves anchoring the nitroimidazole head group near
S78, with Y130 and Y136 participating to position the substrate
for reduction (Figure 6). The identification of these residues and
the lack of classic catalytic residues in the active site suggest
that Ddn functions primarily by precisely orienting PA-824 for
efficient direct hydride transfer from F420 and potentially through
additional transition-state stabilization. Similar mechanisms in
which the protein does not directly participate in hydride transfer
have been suggested for both an F420-utilizing enzyme (Ceh
et al., 2009) and a flavin mononucleotide (FMN)-associated
enzyme of the split barrel-like fold family (di Salvo et al., 2003)
for which ternary donor/acceptor/protein structures are avail-
able. This mechanism is also consistent with previous studies
of the products of PA-824 reduction that suggested a hydride
transfer from F420 to the imidazole ring of PA-824 (Singh et al.,
2008).
The loss of activity toward PA-824 upon N-terminal truncation
of Ddn implies that the N terminus is important for full enzymatic
function. The variability of the N termini among homologous
proteins of the same protein fold also suggests a role in the spec-
ificity of cellular functions. NMR observations and the fact that
a defined structure for the N terminus is only observed in crystals
of Ddn homologs with F420 present support the assignment of
the N terminus as a flexible helix near the active site. The
proposed substrate orientation places the hydrophobic tail
region of PA-824 toward the area occupied by the N terminus
of Ddn (that is absent in the structures presented here), which
is likely to contribute to substrate affinity as well as solvent
exclusion. Extensive mutagenesis studies of the N terminus of
the full-length protein (as an MBP fusion to maintain solubility)
verified that whereas removing F16, F17, or W20 impaired the
enzyme, mutation of all three residues in combination was
required to eliminate the majority of enzymatic activity. A flexible
N terminus that can interact with the prodrug using any of these
three aromatic residues is consistent with the previous synthetic
work and quantitative structure-activity relationship modeling
using PA-824 and its analogs that have suggested that the tail–112, January 11, 2012 ª2012 Elsevier Ltd All rights reserved 107
Table 2. In Vitro Activity of MBP-Ddn and Corresponding nfa33440 Mutants toward PA-824
Ddn
Mutanta kcat
b (s1) KM
c (mM)
kcat/KM
(s1mM1)
kcat/KM
(% WT)
nfa33440
Mutanta kcat
b (s1) KM
c (mM)
kcat/KM
(s1mM1)
kcat/KM
(%WT)
Binding
by NMRd
WTe 2.2 (±0.3) 15.5 (±0.06) 0.14 (±0.02) 100 WTe 0.33 (±0.08) 21.9 (±8.5) 0.016 (±0.002) 100
F16L 2.0 30 0.07 47
F16V 2.2 37 0.06 43
F16A 2.3 37 0.06 44
F17L 2.3 18 0.13 93
F17V 2.5 35 0.07 51
F17A 2.1 22 0.10 68
F16/F17A 2.3 45 0.05 37
F16/F17/
W20Ae
1.2 (±0.01) 104.1 (±4.0) 0.01 (±0.001) 8
W20F 2.5 20 0.13 93
W20L 2.6 36 0.07 51
W20A 2.7 23 0.12 86 W16A 0.2 17 0.012 75 No change
S22A 1.5 15 0.1 71
S22V 1.3 34 0.04 26
F41L 1.9 14 0.13 93
F41A 1.3 26 0.05 36 F35A <0.1 PA-824 weaker
Q42L 1.2 16 0.08 54
Y65Fe 1.1 (±0.04) 10.4 (±1.7) 0.10 (±0.01) 71
Y65L <0.1
Y65A <0.1 M59A <0.1 F420, PA-824
weaker
A76G <0.1 V70A <0.2
S78A <0.1 S72A <0.1
S72V <0.1 PA-824 stronger
K79L <0.1 Q73A <0.2 No change
Y130Fe 0.8 (±0.02) 24.8 (±1.8) 0.03 (±0.004) 21 Y124F 0.28 43 0.007 41
Y130L <0.1 Y124L <0.1
Y130A <0.1
S132V 2.5 52 0.05 34 T126V 0.22 18 0.012 75 No change
S132A 2.1 19 0.11 79
Y133F <0.1 Y127F 0.23 85 0.003 17
Y133L <0.1 Y127L <0.1
Y133A <0.1
D135N 2.7 19 0.14 100 E129A 0.43 74 0.006 36 No change
Y136Fe 2.2 (±0.6) 13.1 (±2.7) 0.16 (±0.02) 114 Y130F 0.31 26 0.012 75
Y136V <0.1
Y136L <0.1 Y130L <0.1
R142A <0.1 R136A <0.1 PA-824 weaker
R142L <0.1 R136Q <0.1 PA-824 weaker
I144V 1.7 17 0.10 69
I144A <0.1 I138A <0.1 PA-824 weaker
I144G <0.1
a See Figure S7 for the locations of all tested mutants.
b For mutants with kcat values <0.2, the KM (and hence kcat/KM) could not be determined because of the very low reaction rates under the assay
conditions.
c KM for PA-824 at saturating [F420].
d See Figures S5 and S6 and Tables S3 and S4 for additional information.
eMeans with standard errors from triplicate experiments are reported for some proteins.
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A 
B
C
Ddn WT
W20A
W20F
F16/F17/W20A
Kd PA-824
(µM) (µM)
Kd F420 Relative
k
cat/Km
100
80
87
13
100 ± 40
162 ± 89
120 ± 103*
0.98 ± 0.20
5.2 ± 2.5
1.6 ± 0.8
46 ± 68*
31 ± 6
Figure 7. Binding of PA-824 to Ddn and Its Mutants Studied by Tryp-
tophan Fluorescence Spectroscopy
(A) Emission spectra in relative fluorescence units (RFUs) of Ddn in the pres-
ence of varying concentrations of PA-824 (0–500 mM) were recorded upon
excitation at 280 nm. The intrinsic spectrum of the ND30 Ddn construct is also
shown. For this experiment, untagged WT Ddn protein was used.
(B) Titration of PA-824 in saturation binding analysis with the MBP fusion of
Ddn WT and mutants monitored at 330 nm. The magnitude of fluorescence
differences (1  F/F0) was used for Kd calculation, as described in Experi-
mental Procedures.
(C) Values determined for MBP-Ddn mutants. Asterisks indicate the triple
mutant which, even at saturating concentration of PA-824, showed less
than 40% quenching, unlike WT MBP-Ddn, for which 80% quenching was
observed. See Figure S8 and Table S5 for CD data on MBP-Ddn mutant
proteins.
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Structure of PA-824-Activating MTB Nitroreductaseregion of these molecules interacts with one or two hydrophobic
aromatic features in Ddn (Kim et al., 2009a, 2009b; Palmer et al.,
2010). The importance of these interactions is also supported by
recent observations of the effect of stereochemistry of the hydro-
phobic tail of drug analogs on interactions with Ddn (Gurumurthy
et al., 2012).
To our knowledge, the costructures presented here are the
first examples of F420 bound to this protein fold. Interestingly,
all other F420-dependent enzymes studied so far, including
FGD1, catalyze reactions at the Si face of F420 (Aufhammer
et al., 2004, 2005; Bashiri et al., 2008; Ceh et al., 2009; Johnson
and Mukhopadhyay, 2005; Klein et al., 1996; Warkentin et al.,Structure 20, 1012001). The binding orientation of this coenzyme toDdn, however,
is similar to that seen in split barrel-like FMN-binding proteins
(Suto et al., 2000), aligning the Re face toward the substrate
and implying a possible shared evolutionary origin of Ddn
proteins with conventional flavoproteins. This binding mode
was supported by the loss of activity of mutants of Y133, Y65,
A76, and K79, thought to anchor the coenzyme.
The apo structure of a distantly related protein, Msmeg_3356,
an F420-dependent aflatoxin reductase fromM. smegmatis, was
recently reported (Taylor et al., 2010). This structure aligns well
to the Ddn core (rmsd is 1.3 A˚ over 109 aligned Ca atoms to
Holo-1) and contains an N-terminal helix similar to the homolog
structures in our study. Although the physiological functions of
these proteins are currently unknown, F420-dependent redox
biochemistry appears to be widespread in Actinobacteria, and
therefore may be important for many pathogenic species.
Ddn is likely to be only one of a class of enzymes that is impor-
tant for activation of nitroimidazole prodrugs, and a more
detailed understanding of the mechanisms of activation and
specificity of these enzymes is certain to be important for devel-
oping not just PA-824 but other candidates in the anti-TB
drug portfolio. Knockout of F420 biosynthesis or fgd1, but not
Rv3547, conferred resistance to CGI-17341, a 4-nitroimidazo-
oxazole (Figure 1) (Manjunatha et al., 2006a). However, this
preference of Ddn for PA-824-like nitroimidazo-oxazines may
not be complete, as disruption of the Rv3547 gene is also
reported to convey resistance to OPC-67683 (nitroimidazo-
oxazole) (Matsumoto et al., 2006; Gurumurthy et al., 2012).
Recent structure-activity relationship modeling also suggests
that 4-nitro and 5-nitro compounds have different targets (Kim
et al., 2009b). Although these data suggest that developing
nitroimidazole compounds will be a complex process, the
success of metronidazole and others in this class should be
encouraging for the current candidates (Barry et al., 2004). Our
efforts only highlight the need for more research into the enzy-
mology and biology of the medical, economic, and humanitarian
challenge presented by TB.
EXPERIMENTAL PROCEDURES
Materials
Coenzyme F420 was purified as described elsewhere (Isabelle et al., 2002;
Gurumurthy et al., 2012). The material was characterized by LC-MS and fluo-
rescence emission scanning (mixture of primarily F420-4, -5, and -6 at 98%
purity) and lyophilized for storage. PA-824 was prepared as described (Baker
et al., 1997).
Protein Expression
The Rv3457 coding sequence was cloned into SpeedET and mutations were
made using PIPE cloning (Klock et al., 2008). Homolog sequences were
synthesized (DNA 2.0) for optimal codon usage in E. coli (see Table S2).
BL21(DE3) (Invitrogen) cells were grown in LB (Becton Dickinson) or TB
(Sigma-Aldrich), moved to 20C at an OD600 of 0.4, induced with IPTG, and
harvested the next day. Proteins for SAD phasing were expressed in seleno-
methionine-containing media. Isotope labeling was done in M9 minimal
medium prepared with [13C]glucose and/or 15NH4Cl and 10%Celtonemedium
(Cambridge Isotope Laboratories) or a mixture of 19 unlabeled and 1 labeled
amino acid (Cellitti et al., 2008). Cells were lysed by sonication in 25 mM
sodium citrate (pH 6.5), 150 mM KCl, 0.5 mM TCEP. Proteins were purified
by Ni-NTA (QIAGEN), TEV digest, a second Ni-NTA column, and a Super-
dex-75 (GE Healthcare) column in a buffer for the final application. WT and
mutant proteins for activity assay were expressed as MBP fusions as–112, January 11, 2012 ª2012 Elsevier Ltd All rights reserved 109
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Structure of PA-824-Activating MTB Nitroreductasepreviously described (Kim et al., 2009b). WTMBP-Ddn was digested with Pre-
cission protease (GE Healthcare) and purified similarly to produce untagged
WT Ddn.
Crystallization and X-Ray Structure Calculations
Proteins were prepared in 10 mM citrate (pH 6.5), 150mMNaCl, 0.5 mM TCEP
at 22, 15–60, or 60 mg/ml for Ddn ND30, ND33, or ND40; or in 20 mM Tris
(pH 8), 150 mM NaCl for homologs at 10–15 mg/ml. Crystals were obtained
by vapor diffusion using 250 nl sitting dropsmixed 1:1 and equilibrated against
50 ml reservoirs (Apo-0/1: 30% PEG6000, 0.1 M MES [pH 6.0] ± 1 M LiCl2;
Apo-2: 1.6 M [NH4]2SO4, 0.1 M citric acid [pH 4.0]; Holo-1: 1.4 M sodium
citrate, 0.1 M HEPES [pH 7.5]; Holo-2: 3.6 M sodium formate, 10% glycerol;
nfa33440: 10% 2-methyl-2,4-pentanediol, 0.1 M sodium acetate [pH 5.0];
nfa18080: 1.6M [NH4]2SO4, 0.1MHEPES [pH 7.0]) in low-profile Greiner plates
(Klock et al., 2008; Santarsiero et al., 2002). Cryoprotectants were added to
drops (Apo-0/1/2, Holo-2: 30% sucrose; nfa18080: 30% glycerol). Data
were collected at the Advanced Light Source at beamline 5.0.2 for Apo-0/1
crystals (at Se peak wavelength of 0.979 A˚) or 5.0.3 for others (0.976 A˚ fixed
wavelength). Data reduction and scaling were performed in HKL2000 (Otwi-
nowski and Minor, 1997). SAD phasing and autobuilding were performed
with SOLVE/RESOLVE (Terwilliger, 2000, 2003; Terwilliger and Berendzen,
1999). Molecular replacement was performed with Phaser (McCoy et al.,
2007) through the ccp4i interface (CCP4, 1994) using only structures from
this study. Iterative model building with Coot (Emsley and Cowtan, 2004)
and maximum-likelihood refinement with PHENIX (Adams et al., 2002, 2010)
were performed until convergence. Ramachandran plots showed outliers
only at K103 (1 of 5 in ASU in Holo-1; 2 of 5 in Holo-2; 2 of 4 at K97 in
nfa33440) and Q73 (2 of 4 in nfa33440), both of which are clearly defined in
the electron density. In the Holo-1, Holo-2, and nfa33440 maps, some
nonspherical density near the F420 cofactor wasmodeled tentatively by waters
during refinement, as it could not be satisfactorily modeled as part of the
N termini or a small molecule. Structural homologies were calculated using
Coot with secondary-structure matching alignment (Krissinel and Henrick,
2004). All protein images were rendered in the PyMOL Molecular Graphics
System (Schro¨dinger, LLC).
NMR Spectroscopy
Samples were prepared in 90% PBS (pH 7.4) with 10% D2O. Isotopically
labeled reagents were from Isotec or Cambridge Isotope Laboratories. NMR
experiments were acquired at 300 K on a 600 MHz Bruker Avance spectrom-
eter equipped with a 5 mm TXI cryoprobe. NMR experiments and backbone
assignment were obtained by standard methods (Mori et al., 1995; Whitehead
et al., 1997) as described in Supplemental Information.
Computational Modeling of PA-824
Docking calculations were performed with software from Schro¨dinger, LLC
using default settings. The Holo-1 crystal structure file was prepared for
docking using the Protein Preparation Wizard tool from the FirstDiscovery
suite. The potential binding site and optimal grid dimensions were determined
with SiteMap. Fully flexible ligand docking was performed with Glide 5.5. The
highest-scoring docking solution was further refined by running an LMOD
conformational search in Macromodel.
Activity Assays
Steady-state kinetic parameters for Ddn and its mutants were determined by
monitoring the oxidation of F420H2 by absorbance at 400 nm as previously
reported (Kim et al., 2009b; Manjunatha et al., 2006a; Singh et al., 2008). Initial
screening of truncation mutants and homologs was performed by monitoring
fluorescence at 400 nm/470 nm.
Ddn Binding to PA-824 and F420 Studies
Fluorescence emission spectra of 1 mM Ddn (excitation at 280 nm) were
recorded at 310–420 nm. Untagged WT Ddn, WT MBP-Ddn, or mutant
MBP-Ddn protein was incubated with varying concentrations of PA-824 or
F420 for 30 min at room temperature before measurements. Apparent dissoci-
ation constant (Kd) values were calculated by fitting the relative change in
intrinsic fluorescence at 330 nm (1 – F/F0) versus ligand concentration to
a one-site binding (hyperbola) model using nonlinear regression (GraphPad110 Structure 20, 101–112, January 11, 2012 ª2012 Elsevier Ltd All rSoftware). F0 is the intrinsic intensity of fluorescence of 1 mM Ddn alone; F is
the fluorescence with a given concentration of ligand; corrections were
made to subtract ligand-associated fluorescence.
Circular Dichroism
Circular dichroism (CD) spectra were recorded from 260–195 nm in a Jasco
J-715 spectropolarimeter, normalized to absorbance spectra for unpolarized
light (McPhie, 2001), and analyzed using the CONTIN program (McPhie,
2008) to determine secondary structure content. See Supplemental Informa-
tion for additional details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures and five tables and can be
found with this article online at doi:10.1016/j.str.2011.11.001.
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